With the recent release of the Netflix Original, The Bleeding Edge, there has been a surge in criticism of the medical device industry and FDA’s premarket review process, both in the news and on social media. Manufacturers of medical devices should be prepared with meaningful and strategic responses to such criticism. Further, in light of recent court rulings excluding key FDA evidence, manufacturers should formulate targeted defenses to mitigate the potential for bias in litigation. This program is designed to assist clients in combating negative perceptions in the media, as well as the potential for courtroom bias, by highlighting how clients can manage the impact of media- and plaintiff-imposed narratives.
